# Roivant Sciences Ltd.: financial statements, quarterly

ROIV · Nasdaq · CIK 1635088 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/roiv.md) · [Financials](/companies/roiv/financials.md) · [Filings](/companies/roiv/filings.md) · [Insiders](/companies/roiv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/roiv/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-09-30) | Q3 FY2023 (2023-12-31) | Q4 FY2023 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q2 FY2024 (2024-09-30) | Q3 FY2024 (2024-12-31) | Q4 FY2024 (2025-03-31) | Q1 FY2025 (2025-06-30) | Q2 FY2025 (2025-09-30) | Q3 FY2025 (2025-12-31) | Q4 FY2025 (2026-03-31) | Q1 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.6](/filings/0001140361-24-046019.md) | [15.6](/filings/0001140361-25-003661.md) | [9.0 d](/filings/0001635088-26-000061.md) | [8.0](/filings/0001140361-25-030001.md) | [4.5](/filings/0001635088-25-000016.md) | [9.0](/filings/0001635088-26-000011.md) | [7.6 d](/filings/0001635088-26-000061.md) | [2.2](/filings/0001635088-26-000090.md) | [1.6](/filings/0001635088-25-000016.md) | [2.0](/filings/0001635088-26-000011.md) | [2.5 d](/filings/0001635088-26-000061.md) | [1.4](/filings/0001635088-26-000090.md) |
| Research and development | $m | [115](/filings/0001140361-24-046019.md) | [108](/filings/0001140361-25-003661.md) | [108 d](/filings/0001635088-26-000061.md) | [121](/filings/0001140361-25-030001.md) | [143](/filings/0001635088-25-000016.md) | [142](/filings/0001635088-26-000011.md) | [145 d](/filings/0001635088-26-000061.md) | [153](/filings/0001635088-26-000090.md) | [165](/filings/0001635088-25-000016.md) | [165](/filings/0001635088-26-000011.md) | [199 d](/filings/0001635088-26-000061.md) | [202](/filings/0001635088-26-000090.md) |
| Selling, general and administrative | $m | [164](/filings/0001140361-23-052721.md) | [197](/filings/0001140361-24-007260.md) | [170 d](/filings/0001140361-24-028145.md) | [149](/filings/0001140361-24-036642.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(214)](/filings/0001140361-24-046019.md) | [5,127](/filings/0001140361-25-003661.md) | [(207) d](/filings/0001635088-26-000061.md) | [(102)](/filings/0001140361-25-030001.md) | [(342)](/filings/0001635088-25-000016.md) | [(274)](/filings/0001635088-26-000011.md) | [(285) d](/filings/0001635088-26-000061.md) | [(285)](/filings/0001635088-26-000090.md) | [(306)](/filings/0001635088-25-000016.md) | [(339)](/filings/0001635088-26-000011.md) | [415 d](/filings/0001635088-26-000061.md) | [(366)](/filings/0001635088-26-000090.md) |
| Interest expense | $m | [9.2](/filings/0001140361-23-052721.md) | [9.4](/filings/0001140361-24-007260.md) | [7.2 d](/filings/0001140361-24-028145.md) | [13.4](/filings/0001140361-24-036642.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [3.2](/filings/0001140361-24-046019.md) | [22.4](/filings/0001140361-25-003661.md) | [(5.8) d](/filings/0001635088-26-000061.md) | [12.0](/filings/0001140361-25-030001.md) | [12.5](/filings/0001635088-25-000016.md) | [(25.6)](/filings/0001635088-26-000011.md) | [49.3 d](/filings/0001635088-26-000061.md) | [4.6](/filings/0001635088-26-000090.md) | [7.0](/filings/0001635088-25-000016.md) | [23.3](/filings/0001635088-26-000011.md) | [98.4 d](/filings/0001635088-26-000061.md) | [(4.0)](/filings/0001635088-26-000090.md) |
| Net income | $m | [(304)](/filings/0001140361-24-046019.md) | [5,096](/filings/0001140361-25-003661.md) | [(151) d](/filings/0001635088-26-000061.md) | [95.3](/filings/0001140361-25-030001.md) | [(230)](/filings/0001635088-25-000016.md) | [169](/filings/0001635088-26-000011.md) | [(206) d](/filings/0001635088-26-000061.md) | [(223)](/filings/0001635088-26-000090.md) | [(114)](/filings/0001635088-25-000016.md) | [(266)](/filings/0001635088-26-000011.md) | [303 d](/filings/0001635088-26-000061.md) | [(190)](/filings/0001635088-26-000090.md) |
| Diluted EPS | $ per share | [(0.40)](/filings/0001140361-24-046019.md) | [6.03](/filings/0001140361-25-003661.md) | not reported | [0.12](/filings/0001140361-25-030001.md) | [(0.31)](/filings/0001635088-25-000016.md) | [0.23](/filings/0001635088-26-000011.md) | not reported | [(0.33)](/filings/0001635088-26-000090.md) | [(0.17)](/filings/0001635088-25-000016.md) | [(0.38)](/filings/0001635088-26-000011.md) | not reported | [(0.26)](/filings/0001635088-26-000090.md) |
| Basic EPS | $ per share | [(0.40)](/filings/0001140361-24-046019.md) | [6.37](/filings/0001140361-25-003661.md) | not reported | [0.13](/filings/0001140361-25-030001.md) | [(0.31)](/filings/0001635088-25-000016.md) | [0.23](/filings/0001635088-26-000011.md) | not reported | [(0.33)](/filings/0001635088-26-000090.md) | [(0.17)](/filings/0001635088-25-000016.md) | [(0.38)](/filings/0001635088-26-000011.md) | not reported | [(0.26)](/filings/0001635088-26-000090.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-09-30) | Q3 FY2023 (2023-12-31) | FY2023 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q2 FY2024 (2024-09-30) | Q3 FY2024 (2024-12-31) | FY2024 (2025-03-31) | Q1 FY2025 (2025-06-30) | Q2 FY2025 (2025-09-30) | Q3 FY2025 (2025-12-31) | FY2025 (2026-03-31) | Q1 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1,408](/filings/0001140361-23-052721.md) | [6,671](/filings/0001140361-24-007260.md) | [6,495](/filings/0001140361-25-020715.md) | [5,679](/filings/0001140361-24-036642.md) | [1,959](/filings/0001140361-24-046019.md) | [1,991](/filings/0001140361-25-003661.md) | [2,715](/filings/0001635088-26-000061.md) | [1,238](/filings/0001140361-25-030001.md) | [1,237](/filings/0001635088-25-000016.md) | [1,478](/filings/0001635088-26-000011.md) | [1,419](/filings/0001635088-26-000090.md) | [1,248](/filings/0001635088-26-000090.md) |
| Current assets | $m | [1,552](/filings/0001140361-23-052721.md) | [6,807](/filings/0001140361-24-007260.md) | [6,732](/filings/0001140361-25-020715.md) | [6,001](/filings/0001140361-24-036642.md) | [5,801](/filings/0001140361-24-046019.md) | [5,364](/filings/0001140361-25-003661.md) | [5,000](/filings/0001635088-26-000061.md) | [4,616](/filings/0001140361-25-030001.md) | [4,512](/filings/0001635088-25-000016.md) | [4,660](/filings/0001635088-26-000011.md) | [5,167](/filings/0001635088-26-000090.md) | [4,742](/filings/0001635088-26-000090.md) |
| Total assets | $m | [2,066](/filings/0001140361-23-052721.md) | [7,313](/filings/0001140361-24-007260.md) | [7,222](/filings/0001140361-25-020715.md) | [6,496](/filings/0001140361-24-036642.md) | [6,206](/filings/0001140361-24-046019.md) | [5,792](/filings/0001140361-25-003661.md) | [5,437](/filings/0001635088-26-000061.md) | [5,033](/filings/0001140361-25-030001.md) | [5,063](/filings/0001635088-25-000016.md) | [5,225](/filings/0001635088-26-000011.md) | [5,709](/filings/0001635088-26-000090.md) | [5,306](/filings/0001635088-26-000090.md) |
| Current liabilities | $m | [266](/filings/0001140361-23-052721.md) | [245](/filings/0001140361-24-007260.md) | [267](/filings/0001140361-25-020715.md) | [215](/filings/0001140361-24-036642.md) | [556](/filings/0001140361-24-046019.md) | [141](/filings/0001140361-25-003661.md) | [149](/filings/0001635088-26-000061.md) | [114](/filings/0001140361-25-030001.md) | [134](/filings/0001635088-25-000016.md) | [152](/filings/0001635088-26-000011.md) | [281](/filings/0001635088-26-000090.md) | [284](/filings/0001635088-26-000090.md) |
| Total liabilities | $m | [740](/filings/0001140361-23-052721.md) | [728](/filings/0001140361-24-007260.md) | [774](/filings/0001140361-25-020715.md) | [601](/filings/0001140361-24-036642.md) | [626](/filings/0001140361-24-046019.md) | [256](/filings/0001140361-25-003661.md) | [250](/filings/0001635088-26-000061.md) | [217](/filings/0001140361-25-030001.md) | [257](/filings/0001635088-25-000016.md) | [251](/filings/0001635088-26-000011.md) | [416](/filings/0001635088-26-000090.md) | [385](/filings/0001635088-26-000090.md) |
| Long-term debt | $m | [389](/filings/0001140361-23-052721.md) | [403](/filings/0001140361-24-007260.md) | [431](/filings/0001140361-24-036642.md) | [312](/filings/0001140361-24-036642.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [49.0](/filings/0001140361-23-052721.md) | [45.7](/filings/0001140361-24-007260.md) | [12.0](/filings/0001140361-24-036642.md) | [12.0](/filings/0001140361-24-036642.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [949](/filings/0001140361-23-052721.md) | [6,090](/filings/0001140361-24-007260.md) | [5,969](/filings/0001140361-25-020715.md) | [5,435](/filings/0001140361-24-036642.md) | [5,153](/filings/0001140361-24-046019.md) | [5,189](/filings/0001140361-25-003661.md) | [4,688](/filings/0001635088-26-000061.md) | [4,346](/filings/0001140361-25-030001.md) | [4,362](/filings/0001635088-25-000016.md) | [4,269](/filings/0001635088-26-000011.md) | [4,527](/filings/0001635088-26-000090.md) | [4,231](/filings/0001635088-26-000090.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-09-30) | Q3 FY2023 (2023-12-31) | Q4 FY2023 (2024-03-31) | Q1 FY2024 (2024-06-30) | Q2 FY2024 (2024-09-30) | Q3 FY2024 (2024-12-31) | Q4 FY2024 (2025-03-31) | Q1 FY2025 (2025-06-30) | Q2 FY2025 (2025-09-30) | Q3 FY2025 (2025-12-31) | Q4 FY2025 (2026-03-31) | Q1 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(196) d](/filings/0001140361-24-046019.md) | [(210) d](/filings/0001140361-25-003661.md) | [(108) d](/filings/0001635088-26-000061.md) | [(193)](/filings/0001140361-25-030001.md) | [(267) d](/filings/0001635088-25-000016.md) | [(207) d](/filings/0001635088-26-000011.md) | [(173) d](/filings/0001635088-26-000061.md) | [(204)](/filings/0001635088-26-000090.md) | [(186) d](/filings/0001635088-25-000016.md) | [(196) d](/filings/0001635088-26-000011.md) | [(164) d](/filings/0001635088-26-000061.md) | [(271)](/filings/0001635088-26-000090.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001140361-24-046019.md) | [0.4 d](/filings/0001140361-25-003661.md) | [0.3 d](/filings/0001635088-26-000061.md) | [1.0](/filings/0001140361-25-030001.md) | [1.0 d](/filings/0001635088-25-000016.md) | [1.8 d](/filings/0001635088-26-000011.md) | [0.8 d](/filings/0001635088-26-000061.md) | [4.0](/filings/0001635088-26-000090.md) | [7.8 d](/filings/0001635088-25-000016.md) | [(4.9) d](/filings/0001635088-26-000011.md) | [1.3 d](/filings/0001635088-26-000061.md) | [0.4](/filings/0001635088-26-000090.md) |
| Share repurchases | $m | [0.0 d](/filings/0001140361-24-046019.md) | [0.0 d](/filings/0001140361-25-003661.md) | [0.0 d](/filings/0001140361-25-020715.md) | [648](/filings/0001140361-25-030001.md) | [106 d](/filings/0001635088-25-000016.md) | [243 d](/filings/0001635088-26-000011.md) | [295 d](/filings/0001140361-25-020715.md) | [208](/filings/0001635088-26-000090.md) | [0.0 d](/filings/0001635088-25-000016.md) | [0.0 d](/filings/0001635088-26-000011.md) | not reported | [207](/filings/0001635088-26-000090.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2022 (2022-09-30) | Q3 FY2022 (2022-12-31) | Q1 FY2023 (2023-06-30) | Q2 FY2023 (2023-09-30) | Q3 FY2023 (2023-12-31) | Q1 FY2024 (2024-06-30) | Q2 FY2024 (2024-09-30) | Q3 FY2024 (2024-12-31) | Q1 FY2025 (2025-06-30) | Q2 FY2025 (2025-09-30) | Q3 FY2025 (2025-12-31) | Q1 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [700](/filings/0001140361-23-052721.md) | [713](/filings/0001140361-24-007260.md) | [759](/filings/0001140361-24-036642.md) | [770](/filings/0001140361-24-046019.md) | [844](/filings/0001140361-25-003661.md) | [782](/filings/0001140361-25-030001.md) | [735](/filings/0001635088-25-000016.md) | [723](/filings/0001635088-26-000011.md) | [680](/filings/0001635088-26-000090.md) | [681](/filings/0001635088-25-000016.md) | [697](/filings/0001635088-26-000011.md) | [721](/filings/0001635088-26-000090.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 722,323,015 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001635088-26-000090.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.